Cisen Pharmaceutical Co., Ltd. (SHA:603367)

Cisen Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	835.3	1,161	983.39	997.95	938.98	661.42
Short-Term Investments	248.01	357.58	154.11	236.27	-	-
Trading Asset Securities	1,672	1,275	1,638	1,550	1,485	1,875
Cash & Short-Term Investments	2,755	2,794	2,775	2,784	2,424	2,537
Cash Growth	-1.29%	0.66%	-0.32%	14.87%	-4.46%	7.36%
Accounts Receivable	1,126	1,257	1,363	1,272	1,048	738.84
Other Receivables	3.79	3.99	4.24	9.25	11.35	8.77
Receivables	1,130	1,261	1,367	1,281	1,060	747.61
Inventory	769.76	810.43	708.22	580.43	594.65	572.12
Other Current Assets	232.63	97.1	119.41	99.63	66.45	93.84
Total Current Assets	4,887	4,962	4,970	4,745	4,145	3,950
Property, Plant & Equipment	1,704	1,546	1,390	1,489	1,591	1,637
Long-Term Investments	5.42	665.48	602.27	265.08	308.01	246.59
Other Intangible Assets	201.63	203.97	211.6	213.03	210.82	207.92
Long-Term Deferred Tax Assets	59.49	77.41	79.83	86.72	81.65	63.12
Long-Term Deferred Charges	1.26	0.47	1.91	3.86	2.05	-
Other Long-Term Assets	738.79	98.74	81.94	12.87	25.54	61.09
Total Assets	7,598	7,554	7,338	6,815	6,364	6,166
Accounts Payable	705.13	549.49	468.01	459.71	434.97	502.13
Accrued Expenses	87.24	114.89	139.77	259.48	214.52	219.74
Short-Term Debt	0.22	71.98	34.8	57.79	130	330
Current Portion of Long-Term Debt	-	32.63	-	-	-	-
Current Portion of Leases	7.69	2.64	3.34	0.3	2.72	-
Current Income Taxes Payable	20.39	11.71	34.67	5.61	1.18	8.24
Current Unearned Revenue	85.32	78.11	100.16	118.78	70.05	70.53
Other Current Liabilities	474.57	627.39	589.17	380.24	365.5	153.7
Total Current Liabilities	1,381	1,489	1,370	1,282	1,219	1,284
Long-Term Debt	14.49	7.7	128.5	100	-	-
Long-Term Leases	2.28	0.89	4.03	0.51	10.91	-
Long-Term Unearned Revenue	58.34	57.17	56.25	65.36	74.43	75.02
Long-Term Deferred Tax Liabilities	5.57	12.28	12.68	11.46	3.87	4.4
Total Liabilities	1,461	1,567	1,571	1,459	1,308	1,364
Common Stock	452.75	452.75	452.78	453.31	453.33	453.35
Additional Paid-In Capital	1,933	1,929	1,919	1,913	1,863	1,844
Retained Earnings	3,714	3,570	3,358	2,989	2,774	2,556
Treasury Stock	-	-	-0.08	-19.77	-32.74	-50.49
Comprehensive Income & Other	-2.26	-2.71	-2.69	-2.93	-3.07	-2.12
Total Common Equity	6,097	5,950	5,727	5,332	5,055	4,801
Minority Interest	39.11	37.39	39.1	23.64	0.75	1
Shareholders' Equity	6,136	5,987	5,766	5,356	5,056	4,802
Total Liabilities & Equity	7,598	7,554	7,338	6,815	6,364	6,166
Total Debt	24.67	115.83	170.67	158.61	143.63	330
Net Cash (Debt)	2,730	2,678	2,604	2,625	2,280	2,207
Net Cash Growth	5.50%	2.81%	-0.79%	15.15%	3.32%	-2.48%
Net Cash Per Share	6.02	5.89	5.75	5.78	5.05	4.88
Filing Date Shares Outstanding	452.75	452.75	452.76	451.36	449.83	447.8
Total Common Shares Outstanding	452.75	452.75	452.76	451.34	449.83	447.8
Working Capital	3,507	3,473	3,600	3,463	2,926	2,666
Book Value Per Share	13.47	13.14	12.65	11.81	11.24	10.72
Tangible Book Value	5,896	5,746	5,516	5,119	4,844	4,593
Tangible Book Value Per Share	13.02	12.69	12.18	11.34	10.77	10.26
Buildings	-	1,277	1,275	1,188	1,191	975.57
Machinery	-	2,109	2,092	1,903	1,797	1,494
Construction In Progress	-	405.8	66.68	207.17	199.71	582.04

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.